Chief AI Office
Posts
📌 6 AI Startups raise $70M+

📌 6 AI Startups raise $70M+

BONUS: The AI Agent Infrastructure Stack From Madrona

March 06, 2025

TODAY’S FUNDING RECAP 🗓️

Freed raises a $30M Series A — Scribe for clinicians
Caddi raises a $5M Seed — "Record-to-code" automation
Ataraxis raises a $20.4M Series A — Cancer care
3 more rounds caught by my funding tracker

Read time: 2 minutes

SHARE CHIEF AI OFFICE

Access Our Database with 1500+ AI Startups For Free

For every 5 referrals, we’ll give you 1 month of Chief AI Office PRO for free

You currently have 0 referrals, only 5 away from adding 1 month to your PRO subscription

Use your unique referral link: https://www.chiefaioffice.xyz/subscribe?ref=PLACEHOLDER

TOP PICKS 📢

1/3

→ Freed

Amount: $30M 🎉

Round: Series A

Lead Investor: Sequoia Capital

Freed is an AI medical scribe that streamlines clinicians' documentation process.

During patient visits, the AI listens to the natural conversation between the clinician and the patient, automatically generating notes organized into the SOAP (Subjective, Objective, Assessment, Plan) format. Clinicians can review and edit these notes, with the platform adapting to individual preferences over time, including phrasing, template layouts, and specific medical terminology.

Notably, the company grew to $10M+ ARR in its first year.

Why Sequoia Capital invested in them

2/3

→ Caddi

Amount: $5M 🎉

Round: Seed

Lead Investor: Ubiquity Ventures

Caddi is a "record-to-code" automation platform.

Users create screen recordings accompanied by audio explanations of their workflows. The platform analyzes these recordings to understand the intent behind user actions and generates fully functional, API-driven automation for repetitive business tasks such as customer onboarding, email management, document organization, data entry, and invoicing.

3/3

→ Ataraxis

Amount: $20.4M 🎉

Round: Series A

Lead Investor: AIX Ventures

Ataraxis AI's flagship product, Ataraxis Breast, is the world's first AI-native prognostic and predictive test for breast cancer.

The core technology behind Ataraxis AI is a proprietary AI model trained on high-resolution images of cancer cells. This model has been developed using hundreds of millions of real images from thousands of patients to provide an accurate assessment of cancer progression.